MERZ PHARMA

History

Year	Detail
1908	Friedrich Merz, a pharmacist and chemist, established his pharmaceutical production plant in Frankfurt.
1911	Merz Pharma introduced Patentex, the first topical contraceptive, into the market.
2002	With Memantine, Merz develops the first active compound worldwide for the treatment of moderate to severe Alzheimer's disease.
2005	Merz introduced an advanced version of neurotoxin, a type-A botulinum toxin free of complex proteins used to treat movement disorders.
2010	Merz acquired BioForm Medical, the U.S.-based dermal filler company, and its flagship product, RADIESSE, to enter the field of medical aesthetics.
2013	Merz Pharma acquired the Swiss company Anteis S.A. to strengthen its aesthetics portfolio and market position in aesthetic medicine. By merging Anteis' operations, Merz Pharma became one of the leading providers worldwide.
2013	With the acquisition of Swiss skincare Company Neocutis, Merz strengthens its core competence in aesthetic medicine.
2014	The company acquired Ulthera Inc. to accelerate its aesthetic growth and expand its ability to provide better and improved aesthetic treatments along the entire continuum of care.
2017	Merz entered a strategic license and co-development agreement with Teijin Ltd., a technology-driven global group operating in materials, healthcare, and IT businesses, to commercialize Xeomin (incobotulinumtoxinA) in Japan.
2020	Merz developed a new business structure that will enable the company to address customer and patient needs better, shorten innovation cycles, and capitalize on new market opportunities. This new organizational structure will consist of three independently operating businesses: Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care.